Dr. Awawu E. Igbinadolor

Internal Medicine
Anson Regional Medical Services Inc.
1328 Patterson St, 
Monroe, NC 
Accepting New Patients
Anson Regional Medical Services Inc.
1328 Patterson St, 
Monroe, NC 

Overview

Awawu Igbinadolor is a primary care provider, practicing in Internal Medicine in Monroe, North Carolina.

Her clinical expertise encompasses COVID-19, Hypertension, Glucocorticoid-Remediable Aldosteronism, and Familial Hypertension.

She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 7 clinical trials. Dr. Igbinadolor is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Adolescent Medicine in NC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Anson Regional Medical Services Inc.
1328 Patterson St, Monroe, NC 28112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
BAT3221032: A Randomized, Controlled Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
BAT3221032: A Randomized, Controlled Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
View 6 Less Clinical Trials

3 Total Publications

The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study.
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study.
Journal: Open forum infectious diseases
Published: November 10, 2023
Similar Doctors
Expertise in
52
conditions
Dr. Benjamin R. Brooks
Internal Medicine
Expertise in
52
conditions
Dr. Benjamin R. Brooks
Internal Medicine

Carolinas Healthcare System

1010 Edgehill Rd N, 
Charlotte, NC 
 (23.8 miles away)
704-446-0155
Languages Spoken:
English
See accepted insurances

Benjamin Brooks is a primary care provider, practicing in Internal Medicine in Charlotte, North Carolina. Dr. Brooks is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Gastrostomy.

Expertise in
39
conditions
Dr. Michael S. Camp
Internal Medicine
Expertise in
39
conditions
Dr. Michael S. Camp
Internal Medicine
Before you request

Atrium Health Primary Care Dove Internal Medicine

1423 E. Franklin St., Suite D, 
Monroe, NC 
 (0.4 miles away)
704-289-6474
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Camp is a primary care provider, practicing in Internal Medicine in Monroe, North Carolina. Dr. Camp is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Familial Hypertension, High Cholesterol, Low Potassium Level, and Hyperlipidemia Type 3. Dr. Camp is board certified in American Board Of Internal Medicine. Dr. Camp is currently accepting new patients.

Expertise in
29
conditions
Dr. Thomas A. Batchelor
Internal Medicine
Expertise in
29
conditions
Dr. Thomas A. Batchelor
Internal Medicine
Before you request

Novant Health Traditions Concierge Medicine

13460 Plaza Road Ext, Suite 100, 
Charlotte, NC 
 (21.3 miles away)
980-488-9450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Batchelor is a primary care provider, practicing in Internal Medicine in Charlotte, North Carolina. Dr. Batchelor is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Cholesteryl Ester Storage Disease, Wolman Disease, Lipidosis with Triglycerid Storage Disease, and Cerebrotendinous Xanthomatosis. Dr. Batchelor is board certified in Internal Medicine. Dr. Batchelor is currently accepting new patients.

Frequently Asked Questions about Dr. Awawu E. Igbinadolor

How do I make an appointment with Dr. Awawu E. Igbinadolor?

You can book an appointment with Dr. Awawu E. Igbinadolor by calling their office at 704-694-6700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Awawu E. Igbinadolor a top-rated expert for COVID-19?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Awawu E. Igbinadolor is classified as an Experienced expert for COVID-19, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Awawu E. Igbinadolor specialize in?

While Dr. Awawu E. Igbinadolor is a Internal Medicine, they have specific expertise in COVID-19, Hypertension, and Glucocorticoid-Remediable Aldosteronism. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Awawu E. Igbinadolor participate in research or clinical trials?

Yes. Dr. Awawu E. Igbinadolor has published 3 articles and abstracts on conditions like COVID-19. You can view a list of Dr. Awawu E. Igbinadolor's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Awawu E. Igbinadolor accept my insurance?

Dr. Awawu E. Igbinadolor accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 704-694-6700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Igbinadolor's expertise for a condition
ConditionClose
        View All 29 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile